CD49b (Integrin alpha 2) Monoclonal Antibody (eBioY418 (Y418)), eBioscience™, Invitrogen™

Description

• Description: The eBioY418 (Y418) monoclonal antibody reacts with human CD49b, the 150-kDa, integrin alpha 2 subunit
• The complex of CD49b non-covalently associated with integrin beta 1 (CD29), also known as VLA-2, is a receptor for collagen and laminin
• This complex is expressed by lymphocytes, activated T cells, monocytes and platelets
• Applications Reported: This eBioY418 (Y418) antibody has been reported for use in flow cytometric analysis
• (Fluorochrome-conjugated eBioY418 is recommended for use in flow cytometry.)
• Applications Tested: This eBioY418 (Y418) antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD49b (Integrin alpha 2, Integrin alpha 2 chain, VLA-2 alpha chain, HM alpha 2) is a member of the integrin family
• It is a glycoprotein with molecular weight of 150 kD, and it complexes with CD29 (Integrin beta 1) to form the heterodimeric integrin VLA-2 (integrin alpha 2 beta 1, or GPIa/IIa) complex
• VLA-2 is an extracellular receptor for laminin, collagen, and fibronectin, and interaction with its ligands results in the activation of intracellular signaling pathways
• It has reported roles in VEGF-induced angiogenesis in vivo, as well as adhesion and lymphocyte activation
• CD49b is expressed by NK cells, NK-T cells, monocytes, platelets, and epithelial cells
• It is also expressed on adaptive immune cells such as T and B cells, specifically on a subset of CD4+ T cells in the spleen, on intraepithelial and lamina propria lymphocytes in the intestine, as well as on a population of peripheral CD4+ type 1 T regulatory (Tr1) cells that co-express LAG-3.